Related Experiment Video
Updated: May 11, 2026
08:37
Induction of Murine Intestinal Inflammation by Adoptive Transfer of Effector CD4+CD45RBhigh T Cells into Immunodeficient Mice
Published on: April 21, 2015
Interleukin-6 mediates the platelet abnormalities and thrombogenesis associated with experimental colitis
Elena Y Senchenkova1, Shunsuke Komoto, Janice Russell
1Department of Molecular and Cellular Physiology, Louisiana State University Health Sciences Center, Shreveport, Louisiana 71130-3932, USA.
The American Journal of Pathology
|May 16, 2013
Summary
Interleukin-6 (IL-6) drives platelet increases and hyperreactivity during experimental colitis. This cytokine mediates thrombocytosis and accelerates thrombus formation in colitis models.
Area of Science:
- Inflammation and Immunology
- Hematology
- Thrombosis Research
Background:
- Colonic inflammation is linked to increased platelet activity and thrombus formation.
- The role of specific cytokines, like IL-6, in these prothrombotic changes during colitis requires elucidation.
Purpose of the Study:
- To determine the contribution of Interleukin-6 (IL-6) to thrombocytosis, platelet aggregation, and thrombosis in experimental colitis.
- To investigate the mechanisms by which IL-6 influences platelet parameters during colitis.
Main Methods:
- Dextran sodium sulfate (DSS)-induced colitis model in wild-type (WT) and IL-6-deficient (IL-6(-/-)) mice.
- Assessment of platelet counts (mature and immature), platelet lifespan, platelet aggregation response to thrombin, and cremaster muscle arteriole thrombus formation.
- Administration of exogenous IL-6 to WT mice.
Main Results:
- DSS-induced colitis caused thrombocytosis and enhanced platelet aggregation and thrombus formation in WT mice.
- IL-6-deficient mice did not develop thrombocytosis or exhibit exaggerated platelet aggregation and thrombus formation.
- Platelet lifespan remained unchanged, suggesting IL-6 enhances thrombopoiesis.
Conclusions:
- IL-6 is a key mediator of thrombocytosis, platelet hyperreactivity, and accelerated thrombus development in experimental colitis.
- The prothrombotic effects of colitis are significantly dependent on IL-6 signaling.
- IL-6 promotes colitis-associated thrombocytosis through enhanced thrombopoiesis.
More Related Videos
Related Concept Videos
01:20Inflammatory Bowel Disease II: Ulcerative Colitis
Ulcerative colitis is a chronic inflammatory disorder of the colon characterized by continuous mucosal inflammation that typically begins in the rectum and extends proximally in a uniform pattern. Its pathogenesis involves a complex interplay of genetic predisposition, immune dysregulation, and environmental influences. These factors converge to impair the colon’s epithelial defenses and promote an exaggerated inflammatory response against luminal contents.Breakdown of the Mucosal BarrierA...
01:25Inflammatory Bowel Disease III: Crohn's Disease
Crohn’s disease is a chronic, relapsing form of inflammatory bowel disease characterized by segmental, transmural inflammation that can affect any part of the gastrointestinal tract. Its pathogenesis arises from a combination of genetic susceptibility, environmental exposures, epithelial barrier dysfunction, and immune dysregulation. Together, these factors lead to an exaggerated immune response against components of the gut microbiome.Genetic and Environmental InfluencesMultiple genetic...
01:27Inflammatory Bowel Disease I: Ulcerative Colitis
Introduction
Inflammatory bowel disease, or IBD, encompasses a group of disorders characterized by chronic inflammation or ulceration of the gastrointestinal tract.
Risk Factors
The exact cause of IBD remains unclear, although it is believed to be due to a mix of genetic, environmental, microbial, and immune factors. Genetic factors are significant in determining susceptibility to IBD, with family history being a critical risk factor. Individuals with a first-degree relative who has IBD are at...
Inflammatory bowel disease, or IBD, encompasses a group of disorders characterized by chronic inflammation or ulceration of the gastrointestinal tract.
Risk Factors
The exact cause of IBD remains unclear, although it is believed to be due to a mix of genetic, environmental, microbial, and immune factors. Genetic factors are significant in determining susceptibility to IBD, with family history being a critical risk factor. Individuals with a first-degree relative who has IBD are at...
01:20Inflammatory Bowel Disease IV: Clinical Manifestations
Inflammatory bowel disease (IBD) encompasses two major chronic disorders—ulcerative colitis and Crohn’s disease—each characterized by relapsing episodes of gastrointestinal inflammation. Although they share certain clinical features, their patterns of involvement and manifestations differ in ways that aid diagnosis and guide management.Ulcerative ColitisUlcerative colitis is limited to the colon and rectum and involves continuous inflammation of the mucosal layer. The disease course is marked...
01:29Drugs for Treatment of Crohn's Disease in IBD Using Immunomodulatory Agents
Crohn's disease is an inflammatory bowel disorder marked by chronic inflammation of the GI tract. Various treatment strategies for Crohn's disease are employed, such as immunomodulatory agents, glucocorticoids, and biologics or anti-TNF therapy. Azathioprine (Imuran), a commonly used immunomodulatory drug for Crohn's disease, is converted in the body to mercaptopurine, which inhibits purine biosynthesis and cell proliferation. Both are utilized in severe cases of Inflammatory Bowel Disease...
01:26Inflammatory Bowel Disease I: Introduction
Inflammatory bowel disease is a group of chronic disorders marked by recurrent inflammation of the gastrointestinal tract due to an abnormal immune response against gut microflora. This leads to tissue damage. The two main forms are Crohn’s disease and ulcerative colitis.Crohn’s DiseaseCrohn’s disease is a relapsing inflammatory disorder that can affect any part of the GI tract, from the mouth to the anus. It involves all layers of the bowel wall (transmural) and shows “skip lesions” in which...